Clinical Trials Preclinical Studies Phase 3 Trials Regulatory Approval FDA Approval Monoclonal Antibodies Cancer Therapies Regulatory Affairs Therapeutics Phase Trials Personalized Medicine Therapeutic Applications Experimental Treatments FDA Approval Process Gender Differences Repurposing Drugs Ezogabine Chimeric Peptides Mechanism of Action Targeted Therapy Nektar Therapeutics Antifungal Research FDA Regulations Anti-inflammatory Medications Patient Trials Regulatory Agencies Antibody Therapy Accelerated Approval Market Competition mRNA Innovations Cancer Drugs Antimicrobial Agents Synthetic Biology Safety Trials Molecular Entities Weight Loss Medications Artificial Intelligence Trial Phases Weight Management Programs Peptide Medicines Antibodies Combination Therapies Research Phases
Want to see what podcasts are saying about this topic? Search across 165K+ podcasts. Explore Radar
The agreement gives Sandoz global ex-China registration and sales rights under a $322 million milestone framework that could accelerate Henlius’ early-stage antibody programs.
